MOLBIO

The earnings call for Molbio Diagnostics Limited's Q1 FY27 discusses the company's growth in its Truenat molecular diagnostics platform, which has over 12,500 machines installed globally and 43 assays for 30 diseases. Management highlighted the recurring revenue model from consumables, with 75% of revenue coming from test kits. The company emphasized its R&D focus, with 5-6% of revenue allocated to innovation, and noted 207 registered patents. Strategic acquisitions include Prognosys (digital X-rays) and OptraScan (digital pathology), with the latter recently receiving US FDA clearance. Financials for Q1 FY27 showed revenue of ₹408 crores, EBITDA of ₹104 crores, and a 25% margin. Guidance for FY27 includes top-line growth of ~25% and EBITDA margins of 24-25%. The company also discussed expansion into European and US markets, with the Truenat CT/NG test kit certified under EU IVDR. Challenges include scaling production and managing the transition from traditional diagnostic methods to molecular testing in India's public health programs.

The document emphasizes growth in installed base, recurring revenue, R&D investment, and strategic acquisitions, with management highlighting strong financial performance and expansion opportunities.